9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Window of Opportunity Study of VS-6063 (Defactinib) in Participants With Surgical Resectable Malignant Pleural Mesothelioma.

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > Window of Opportunity Study of VS-6063 (Defactinib) in Participants With Surgical Resectable Malignant Pleural Mesothelioma.

Window of Opportunity Study of VS-6063 (Defactinib) in Participants With Surgical Resectable Malignant Pleural Mesothelioma.

Estimated reading time: < 1 min

Condition: Malignant Pleural Mesothelioma

Estimated Enrollment: 38

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Recruiting

Study Results: No Results Available

Outcome Measures: Assess biomarker responses to VS-6063 in tumor tissue,  Evaluate the safety of VS-6063 (defactinib),  Evaluate the pharmacokinetics of VS-6063 (defactinib), To evaluate the tumor response to VS-6063 (defactinib)

Interventions: VS-6063,

Phase:

Study Type: Interventional

Study Design: Intervention Model: Single Group Assignment, Masking: None (Open Label), Primary Purpose: Treatment,

Primary Completion Date: September 2019

Completion Date: September 2019

Last  Posted Date: October 15, 2018

Location: Brigham and Women’s Hospital, Boston, Massachusetts, United States

Website Link: https://ClinicalTrials.gov/show/NCT02004028

Was this article helpful?
Dislike 0